ARTV Artiva Biotherapeutics, Inc.
Price Chart
Executive Summary
RA Capital Management, a director and 10% owner, purchased 1.43 million shares of Artiva Biotherapeutics for $11.14 million across five open-market trades from June 9-12, 2026. The purchase represents approximately 4.9% of the company's $227 million market cap, a highly material insider buying signal that indicates strong conviction in the company's prospects.
Key Financial Metrics
Actionable Insight
This is a massive insider buy from a major shareholder that should be read as a strong bullish signal. Traders should monitor for upcoming catalysts such as clinical trial updates or partnership announcements. Given the historical over-scoring on ARTV (past long calls have been wrong), size the position carefully and consider a price target aligned with the purchase range up to $8.99.
Key Facts
- Total insider purchase of $11.14 million over 5 trades from June 9-12, 2026
- Purchase represents ~4.9% of $227M market cap, well above the 2% materiality threshold
- Only insider is RA Capital Management, L.P., acting as both director and 10% owner
- Prices ranged from $6.91 to $8.99 per share, with largest trades at higher prices
- Recent 30-day insider activity shows $12.3M in total buys vs $450K in sells, indicating net accumulation
Financial Impact
$11.14 million purchase, approximately 4.9% of market cap
Risk Factors
- Historical performance shows that prior bullish reports on ARTV have been wrong, with average T+20 loss of -12.37%
- Biotech single-product risk and clinical-stage volatility
- Insider could be buying to maintain ownership percentage ahead of dilution or strategic move
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001231919-26-000656 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 16, 2026
2d ago
|
Insider Buy
| $9.94 $9.82 | ▼ −1.21% | ▼ −1.99% | $9.94 (−0.00%) |
|
Jun 8, 2026
11d ago
|
Press Release
| $6.80 $7.27 | ▲ +6.91% | ▲ +7.21% | $9.94 (+46.18%) |
|
May 20, 2026
4w ago
|
Insider Cluster
| $7.84 $7.99 | ▼ −1.91% | ▼ −1.72% | $9.94 (−26.79%) |
|
May 19, 2026
4w ago
|
Press Release
| $7.84 $7.99 | ▲ +1.91% | ▲ +1.72% | $9.94 (+26.79%) |
|
May 19, 2026
4w ago
|
8-K
| $8.55 $7.84 | ▼ −8.30% | ▼ −9.34% | $9.94 (+16.26%) |
|
May 19, 2026
4w ago
|
Press Release
| $8.55 $7.84 | ▼ −8.30% | ▼ −9.34% | $9.94 (+16.26%) |
|
May 18, 2026
4w ago
|
144
| $8.55 $7.84 | ▼ −8.30% | ▼ −9.34% | $9.94 (+16.26%) |
|
May 18, 2026
4w ago
|
144
| $8.55 $7.84 | ▼ −8.30% | ▼ −9.34% | $9.94 (+16.26%) |
|
May 8, 2026
5w ago
|
8-K
| $10.60 $10.60 | · 0.00% | ▼ −0.14% | $9.94 (+6.23%) |
|
May 8, 2026
6w ago
|
8-K
| $10.89 $10.60 | ▼ −2.66% | ▼ −2.89% | $9.94 (−8.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access